Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Gebski

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
British Journal of Cancer|September 6, 2006
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotideJ Cebon, M Findlay, C Hargreaves, et al.
British Journal of Cancer|September 15, 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trialJ Lee, A Dean, T Price, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
British Journal of Cancer|September 6, 2006
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotideJ Cebon, M Findlay, C Hargreaves, et al.
British Journal of Cancer|September 15, 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trialJ Lee, A Dean, T Price, et al.
Pageof 11